By Lina carolina 
Researchers from the Francis Crick Institute, the UCL Cancer Institute, and University College London Hospitals (UCLH) have unveiled a groundbreaking diagnostic tool named ORACLE, demonstrating its enhanced ability to predict lung cancer survival at the point of diagnosis compared to current clinical risk factors. This innovation holds significant promise for optimizing treatment decisions, particularly for individuals diagnosed with stage 1 lung cancer, potentially leading to a reduction in cancer recurrence and metastasis.
A New Era in Lung Cancer Prognosis
The pioneering research, published in the esteemed journal Nature Cancer, details the rigorous testing of the ORACLE assay in a cohort of 158 lung cancer patients enrolled in the Cancer Research UK-funded TRACERx study. The findings unequivocally established ORACLE’s superior predictive power for patient survival, surpassing established clinical benchmarks such as tumour stage. This development addresses a critical unmet need in lung cancer management, where precise prognostic tools are essential for tailoring therapies to individual patient profiles.
Lung cancer remains a formidable global health challenge, consistently ranking as the leading cause of cancer-related mortality worldwide. Despite advancements in screening and treatment, the five-year survival rate for lung cancer, while improving, still lags behind many other common cancers. For instance, in the UK, while overall cancer survival has doubled in the last 50 years, lung cancer survival rates, though better than in the 1970s, remain one of the more challenging to improve. This underscores the urgent necessity for more accurate tools to stratify patients based on their risk of recurrence and response to therapy.
Addressing the Limitations of Current Prognostic Methods
The development of ORACLE in 2019 was a direct response to the persistent lack of reliable biological markers in lung cancer that could reliably identify patients at higher risk of their cancer returning or spreading. Traditional diagnostic methods often rely on macroscopic tumour characteristics and limited genetic analysis. When doctors obtain a tumour sample for biopsy, they typically analyse less than 1% of the tumour mass. This limited sampling can be a significant drawback, as the genetic makeup of a tumour can vary substantially across different regions within the same tumour. This genetic heterogeneity means that a single biopsy might not capture the full picture of the cancer’s behaviour, potentially leading to misjudgments in treatment strategies.
ORACLE’s Innovative Approach to Tumour Profiling
ORACLE’s innovative methodology circumvents this sampling limitation by analysing gene expression levels across the entire tumour. Instead of focusing on a few specific genes or regions, ORACLE assesses genes that are expressed at high or low levels throughout all parts of the tumour. This comprehensive approach provides a more holistic and representative snapshot of the tumour’s biological characteristics and its potential for aggressive behaviour.
The implications of this comprehensive profiling are particularly profound for patients diagnosed with stage 1 lung cancer. This early stage of the disease typically warrants surgical intervention without the immediate addition of chemotherapy. However, a significant proportion, approximately a quarter, of these early-stage patients experience cancer recurrence. This suggests that a subset of stage 1 patients may have benefited from more intensive monitoring or adjuvant chemotherapy. ORACLE’s ability to identify these higher-risk individuals at the point of diagnosis could enable clinicians to proactively recommend such interventions, thereby potentially averting recurrence and improving long-term outcomes.
Predictive Power for Stage 1 Lung Cancer Patients
The new findings from the TRACERx study provide compelling evidence for ORACLE’s utility in this crucial patient group. The research demonstrated that ORACLE could accurately identify stage 1 lung cancer patients who had a lower probability of survival. This critical insight allows doctors to consider chemotherapy in addition to surgery for these individuals, a therapeutic strategy not routinely offered to all stage 1 patients based on current standards. The fact that conventional clinical standards failed to provide this level of prognostic detail for stage 1 patients highlights the transformative potential of ORACLE.
Linking Prognosis to Tumour Metastasis and Drug Response
Beyond its prognostic capabilities, the study also revealed a significant correlation between high ORACLE risk scores and specific regions within the tumour that exhibited a higher propensity for metastasis. This suggests that ORACLE not only predicts overall survival but also offers insights into the mechanisms driving cancer spread.
Furthermore, in a comprehensive analysis of 359 current and potential lung cancer drugs, the researchers discovered that a high ORACLE risk score was associated with a better response to certain chemotherapy regimens, notably platinum-based drugs such as cisplatin. This finding is particularly noteworthy because tumour regions with high ORACLE scores are frequently characterized by genomic instability, specifically chromosomal instability. This genomic instability is a hallmark of many cancers and is particularly susceptible to the DNA-damaging effects of platinum-based chemotherapy. The research team’s recent findings have also identified alterations in a key gene, FAT1, as a driver of chromosomal instability, and this gene’s variations are among those assessed by ORACLE. This provides a biological rationale for ORACLE’s predictive power regarding chemotherapy response.
Future Directions and Clinical Translation
The next crucial phase for the researchers involves rigorously validating ORACLE in larger patient cohorts. A critical step will be to compare outcomes for patients with high ORACLE scores who receive standard care versus those who undergo more intensive surveillance or receive adjuvant chemotherapy. This comparative analysis aims to definitively establish whether the insights provided by ORACLE translate into tangible improvements in survival rates, even for patients diagnosed at the earliest stages of lung cancer.
Expert Perspectives on ORACLE’s Potential
The researchers involved in this landmark study have expressed considerable optimism about ORACLE’s potential impact. Dhruva Biswas, a Translation Fellow at the Crick and co-first author, highlighted the test’s ability to predict survival rates in early-stage patients. He emphasized that with further validation in larger cohorts, ORACLE could empower clinicians to make more informed treatment decisions, effectively translating the understanding of cancer evolution into clinical practice.
Yun-Hsin Liu, a Research Assistant at the UCL Cancer Institute and co-first author, reiterated the team’s goal of building upon previous work and demonstrating ORACLE’s predictive capabilities at diagnosis. She noted that the study has also shown ORACLE’s potential to predict chemotherapy responsiveness and the likelihood of cancer spread, offering a comprehensive assessment of a patient’s cancer trajectory.
Charles Swanton, Deputy Clinical Director and Head of the Cancer Evolution and Genome Instability Laboratory at the Crick, and co-senior author, underscored the global burden of lung cancer. He stressed the urgent need for improved markers to accurately classify tumours and identify high-risk individuals. Swanton confirmed that efforts are underway with the Crick’s Translation team and industry partners to expedite the transition of ORACLE into a clinically deployable test.
Paul Mercer, Head of Industry Partnerships at the Crick Translation team, described the development as a significant stride in translating complex knowledge of lung cancer mutations into a diagnostic tool. He emphasized its role in prioritizing patients for the most effective therapies and expressed enthusiasm for collaborating with partners to maximize patient benefit.
Dani Edmunds, Science Engagement Manager at Cancer Research UK, acknowledged the progress made in cancer survival over the past five decades but highlighted the disparities across different cancer types. She stated that while lung cancer survival has improved, it remains a formidable challenge. Edmunds posited that new tests like ORACLE could empower doctors to personalize treatment strategies, thereby enhancing the chances of successful outcomes. She concluded that while further large-scale trials are necessary, these initial results represent a promising step towards more personalized approaches to lung cancer treatment, ultimately aiming for longer and better lives for patients.
Broader Implications and Future Research
The development of ORACLE represents a significant advancement in the field of precision oncology for lung cancer. By providing a more accurate and comprehensive assessment of a patient’s prognosis at the time of diagnosis, ORACLE has the potential to revolutionize treatment decision-making. For stage 1 lung cancer patients, this could mean the difference between standard care and proactive interventions that significantly reduce the risk of recurrence. For patients with more advanced disease, ORACLE’s predictive capabilities regarding chemotherapy response could lead to more tailored and effective treatment regimens, minimizing exposure to ineffective therapies and maximizing patient benefit.
The study’s reliance on the TRACERx study, a large-scale, multi-institutional research initiative focused on understanding the evolution of lung cancer, lends considerable weight to its findings. The TRACERx study has been instrumental in generating crucial insights into the biological complexity of lung cancer, and ORACLE’s success within this framework highlights its potential to translate complex biological discoveries into tangible clinical applications.
The National Institute for Health and Research (NIHR) UCLH Biomedical Research Centre has provided crucial support for this research, underscoring the collaborative effort between academic institutions and funding bodies in driving medical innovation. As ORACLE moves towards broader clinical validation, its impact on improving outcomes for lung cancer patients worldwide is eagerly anticipated. This research not only signifies a leap forward in diagnostic technology but also embodies the ongoing commitment to transforming the landscape of cancer treatment through personalized and data-driven approaches.
